Can American adults receive a fourth dose of the COVID-19 vaccine? The pharmaceutical company Moderna has requested the Food and Drug Administration to approve a fourth dose of the COVID-19 vaccine as a booster dose for all adults.
However, rival pharmaceutical company Pfizer’s request was to approve booster shots for the elderly only.
US authorities are laying the foundation for providing additional booster immunity to enhance vaccine protection against serious illness and death from COVID-19. The White House warns that Congress needs to approve more money “urgently.” The federal government reserves higher doses of the COVID-19 vaccine for either additional boost or variant-specific immunity.
US health officials are currently recommending a series of two doses of the Moderna vaccine and a booster dose several months later.
Moderna stated that the request for additional doses was based on “recently published data generated in the United States and Israel after the advent of Omicron.”
Last Tuesday, Pfizer and its partner BioNTech requested US regulatory authorities to approve a booster dose of the COVID-19 vaccine for the elderly.
A New York-based pharmaceutical company and its German partner, BioNTech SE, is the second booster of the vaccine for people over the age of 65 who have already received a booster of any of the licensed COVIDs. He said he was seeking an emergency permission for Comirnaty. 19 vaccines.
Pfizer and BioNTech said Israel submitted the data to the FDA. The FDA began offering a fourth shot to seniors and health care workers last year as a variant of Omicron was in circulation.
In a press release announcing its application to the FDA, Pfizer analyzed Israeli medical records and confirmed that people over the age of 60 who received a second booster had only three doses. He said he was half of the responders who did not. In addition, the likelihood of developing severe COVID-19 was one-quarter in the second booster group.
Pfizer’s FDA application also included the results of an unspecified clinical trial that provided Israeli healthcare workers who wanted it with a second booster shot: 154 people who received the fourth shot. Of the workers, neutralizing antibodies increased 7-8 times. Antibodies specific to the Omicron variant increased 8- to 10-fold, according to Pfizer.
Pfizer’s press release does not know the names of the researchers conducting the study design and trials, but these findings reflect some of the population covered by the New England Journal of Medicine study on Wednesday. It seems that.
Vaccine experts are waiting for a full explanation of the data quoted by Pfizer, so they point out the newly published Israeli study as evidence that the discussion about the second booster is premature. did.
In the United States, people over the age of 12 can receive a single booster dose of the Cominati vaccine if they have already completed the Pfizer and BioNTech double dose regimens. Comirnaty boosters are available to those over the age of 18.
A study from the Centers for Disease Control and Prevention, published earlier this year, found that people who received a third dose generally performed better for the Delta and Omicrons variants than those who received only a second dose. did.
Cases of COVID-19 have declined sharply from the peak of winter, but there are signs that infection may increase further in the coming weeks. More than one-third of US CDC wastewater sample sites showed an increasing trend of the virus earlier this month. ..
Pfizer is also studying Omicron-specific vaccines and hybrid shots targeting Omicron along with previous variants. The company plans to report data on these efforts in April.
The CDC recommends that some people with immunodeficiency take three primary series mRNA shots and a fourth shot as boosters.
Dr. Paul Offit, an infectious disease expert at the Philadelphia Children’s Hospital, said the three shots of the vaccine should probably be considered the major series for older and sick Americans. It hasn’t been made yet, he added.
For most people, a few doses or an mRNA vaccine virtually eliminates the threat that the infection progresses to serious illness or death, Offit said. It will be difficult to show that the immune system needs more vaccines to protect itself from SARS-CoV. -2 virus, he added.
“To get over this pandemic, we need to be aware that protection from mild illness will not last long,” says Ofit. The key is to admit that the infection is nothing more than snuffs and coughs. “As long as protection from serious illness continues, we should consider it a victory,” he said.
–The Associated Press, Bloomberg News, Los Angeles Times contributed to this report